Find Inclisiran manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

API SUPPLIERS

read-more
read-more

01

EUROAPI

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Under De... arrow-down AUDIT
EUROAPI Compnay Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

04

Apextide

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

Apextide

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
ACI Convention
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Agilent Technologies

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

Agilent Technologies

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
ACI Convention
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

Anhui Ribobay Pharmaceutical Co.,L...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

07

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

08

Gyma Laboratories of America

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

Gyma Laboratories of America

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
ACI Convention
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Shanghai Desano Chemical Pharmaceu...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ACI Convention
Not Confirmed
arrow

Shanghai Desano Chemical Pharmaceu...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
ACI Convention
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Aus. Peptide Conference
Not Confirmed
arrow
arrow
Aus. Peptide Conference
Not Confirmed

INCLISIRAN

NDC Package Code : 70596-1002

Start Marketing Date : 2021-12-27

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

02

Aus. Peptide Conference
Not Confirmed
arrow
arrow
Aus. Peptide Conference
Not Confirmed

INCLISIRAN SODIUM

NDC Package Code : 42931-712

Start Marketing Date : 2024-11-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

EUROAPI

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content

Inclisiran

About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately ...

EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
EUROAPI Compnay Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Inclisiran

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Inclisiran

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

04

OTS 2025
Not Confirmed
arrow
arrow
OTS 2025
Not Confirmed

Inclisiran

About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuzhou, within the Nanjing metropolitan area, Ribobay Pharmaceutical specializes in the therapeutic oligonucleotides CXO field. This strategic focus aligns with General Biol's broader expansion plans for its CXO business, making Ribobay a crucial component of the company's ventures in this domain.
blank

05

OTS 2025
Not Confirmed
arrow
arrow
OTS 2025
Not Confirmed

Inclisiran

About the Company : For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacture...

For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacturers who rely on our integrity, expertise, and follow-through have been with us for three, four, and even five decades.
blank

06

OTS 2025
Not Confirmed
arrow
arrow
OTS 2025
Not Confirmed

Inclisiran

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718908200,"product":"INCLISIRAN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"4","unit":"GMS","unitRateFc":"1500","totalValueFC":"6059","currency":"USD","unitRateINR":"126450","date":"21-Jun-2024","totalValueINR":"505800","totalValueInUsd":"6059","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4120285","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"ROOM 1101, BUILDING A, NO.58,TANZHU ROAD,SHANGHAI CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736101800,"product":"INCLISIRAN INCLISIRAN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1302","totalValueFC":"130759.9","currency":"USD","unitRateINR":"112753.2","date":"06-Jan-2025","totalValueINR":"11275320","totalValueInUsd":"130759.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"7642182","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"ROOM 1101, BUILDING A, NO.58, TANZHU ROAD, SHANGHAI CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1737570600,"product":"\\\"FOC\\\" INCLISIRAN SODIUM IMP\\'S (AS02-3-IM2 -AS02-6-IM28) (18BAGS=300 MG)\\\"FOC\\\" INCLISIRAN SODIUM IMP\\'S (AS02-3-IM2 -AS02-6-IM28) (18","address":"564\/A\/22, ROAD NO.92","city":"HYDERABAD,ANDHRA PRADESH","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"MYLAN LABORATORIES LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.3","unit":"GMS","unitRateFc":"20","totalValueFC":"6.1","currency":"USD","unitRateINR":"1742","date":"23-Jan-2025","totalValueINR":"522.6","totalValueInUsd":"6.1","indian_port":"Bangalore Air","hs_no":"29349990","bill_no":"7949796","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"No. 28, Jian an Road, High-Tech Ind ustrial Development Zone, Yangzhou City, Jiangsu Province 225100, P.R.","customerAddress":"564\/A\/22, ROAD NO.92"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1744741800,"product":"INCLISIRAN (LIST 4 SR.NO.148) INCLISIRAN (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH COLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"1090000","totalValueFC":"330813.2","currency":"USD","unitRateINR":"94394000","date":"16-Apr-2025","totalValueINR":"28318200","totalValueInUsd":"330813.2","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"9512789","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"ROOM 1101, BUILDING A, NO.58,TANZHU ROAD, SHANGHAI, SDNF CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1746729000,"product":"INCLISIRAN SODIUM (LIST 4 SR.NO.148) INCLISIRAN SODIUM (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH COLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"48.1","unit":"GMS","unitRateFc":"500","totalValueFC":"24148.6","currency":"USD","unitRateINR":"42775","date":"09-May-2025","totalValueINR":"2057477.5","totalValueInUsd":"24148.6","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"9962677","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"ROOM 1101, BUILDING A, NO.58,TANZHU ROAD, SHANGHAI, SDNF CHINA","customerAddress":"MUMBAI CENTRAL,"}]
21-Jun-2024
09-May-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 04, 2025

blank

01

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

August 04, 2025

blank

Details:

Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 31, 2025

blank

02

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

July 31, 2025

blank
  • Development Update

Details:

Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.


Lead Product(s): Inclisiran Sodium,Inclisiran

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 03, 2025

blank

03

Duke University

Country
arrow
Aus. Peptide Conference
Not Confirmed

Duke University

Country
arrow
Aus. Peptide Conference
Not Confirmed

Lead Product(s) : Inclisiran Sodium,Inclisiran

Therapeutic Area : Undisclosed

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

April 03, 2025

blank
  • Development Update

Details:

Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.


Lead Product(s): Inclisiran Sodium,Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2025

blank

04

University of California, San Diego

Country
arrow
Aus. Peptide Conference
Not Confirmed

University of California, San Diego

Country
arrow
Aus. Peptide Conference
Not Confirmed

Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

March 10, 2025

blank

Details:

Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.


Lead Product(s): Pelacarsen,Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 07, 2025

blank

05

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

February 07, 2025

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

06

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

07

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 28, 2024

blank

08

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

August 28, 2024

blank

Details:

Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 09, 2024

blank

09

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

July 09, 2024

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 26, 2024

blank

10

Aus. Peptide Conference
Not Confirmed
Aus. Peptide Conference
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

April 26, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Aus. Peptide Conference
Not Confirmed
arrow
arrow
Aus. Peptide Conference
Not Confirmed

INCLISIRAN SODIUM

Brand Name : LEQVIO

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)

Packaging :

Approval Date : 2021-12-22

Application Number : 214012

Regulatory Info : RX

Registration Country : USA

blank

02

Country
Aus. Peptide Conference
Not Confirmed
arrow

Country
arrow
Aus. Peptide Conference
Not Confirmed

inclisiran

Brand Name : Leqvio

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

Country
Aus. Peptide Conference
Not Confirmed
arrow

Country
arrow
Aus. Peptide Conference
Not Confirmed

inclisiran

Brand Name : Leqvio

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

NOVARTIS

Switzerland
FNCE
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
FNCE
Not Confirmed

INCLISIRAN SODIUM

Brand Name : LEQVIO

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)

Approval Date : 2021-12-22

Application Number : 214012

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Leqvio

Inclisiran

arrow
FNCE
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
FNCE
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 12

2020 Revenue in Millions : 0

Growth (%) : New Launch in 2021

blank

02

Brand Name : Leqvio

Inclisiran

arrow
FNCE
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
FNCE
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 112

2021 Revenue in Millions : 12

Growth (%) : 833

blank

03

Brand Name : Leqvio

Inclisiran

arrow
FNCE
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
FNCE
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 355

2022 Revenue in Millions : 112

Growth (%) : 217

blank

04

Brand Name : Leqvio

Inclisiran

arrow
FNCE
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
FNCE
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2024 Revenue in Millions : 754

2023 Revenue in Millions : 355

Growth (%) : 112

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty